Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-68,000
Closed -$2.26M 380
2023
Q3
$2.26M Buy
+68,000
New +$2.4M 0.32% 54
2023
Q2
Sell
-35,000
Closed -$1.43M 540
2023
Q1
$1.43M Buy
+35,000
New +$1.51M 0.28% 66
2022
Q2
Sell
-25,000
Closed -$1.27M 570
2022
Q1
$1.29M Buy
25,000
+21,450
+604% +$1.11M 0.17% 100
2021
Q4
$210K Sell
3,550
-10,051
-74% -$498K 0.03% 333
2021
Q3
$585K Buy
+13,601
New +$603K 0.08% 230
2021
Q2
Sell
-10,000
Closed -$362K 639
2021
Q1
$362K Buy
+10,000
New +$355K 0.04% 283

Other funds holding PFE

Shay Capital's PFE Position: Q4 2023 in Review

Shay Capital sold out of Pfizer (PFE) in Q4 2023, closing a stake of 68,000 shares — an estimated $2.26M sold.

Shay Capital first reported a position in PFE in Q1 2021 and held it in 6 quarters. The position peaked at $2.26M in Q3 2023. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

  • Shay Capital reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
  • Shay Capital sold 68,000 Pfizer shares in Q4 2023, an estimated $2.26M.
  • Shay Capital first reported a position in Pfizer in Q1 2021 and held it in 6 quarters.
  • Shay Capital's Pfizer position peaked at $2.26M in Q3 2023.
  • 2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Shay Capital's 13F filing for Q4 2023, filed 14 Feb 2024.